|
US2019247326A1
|
|
Identification of seizure susceptibility region in wolf-hirschhorn syndrome and treatment thereof
|
|
WO2017210456A1
|
|
Systems, devices and methods for improved analysis and storage of genotypic and phenotypic data
|
|
WO2015157571A1
|
|
Genetic markers associated with chromosomal deletion and duplication syndromes
|
|
EP3084007A2
|
|
Diagnosis and prediction of austism spectral disorder
|
|
EP2917733A2
|
|
Methods and compositions for the diagnosis of multiple sclerosis
|
|
EP2904117A1
|
|
Genetic markers associated with asd and other childhood developmental delay disorders
|
|
EP2524220A1
|
|
Risk factors of cigarette smoke-induced spirometric phenotypes
|
|
WO2011082433A1
|
|
Metabolomics-based biomarkers for lung function
|
|
EP2521797A1
|
|
Dna methylation biomarkers of lung function
|
|
EP2521730A1
|
|
Gene biomarkers of lung function
|
|
WO2011082435A1
|
|
Biomarkers of lung function
|
|
US2011160070A1
|
|
Copd biomarker signatures
|
|
EP2038413A2
|
|
Apparatus, compositions, and methods for assessment of chronic obstructive pulmonary disease progression among rapid and slow decline conditions
|
